Zileuton therapy for Sjogren-Larsson syndrome

Recruiting

• Conditions: Sjogren-Larsson syndrome; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders

• Registration Number: ACTRN12606000320550
• Lead Sponsor: South East Sydney Area Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-07-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

Paediatric patients with a clinical diagnosis and biochemically confirmed Sjogren-Larsson syndrome.

Exclusion Criteria

Adult patients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Itch scores[At O, 3, and 7 months (crossover period), and 19 months (open label)];Clinical neuropsychological evaluation[At O, 3, and 7 months (crossover period), and 19 months (open label)];EEG[At O, 3, and 7 months (crossover period), and 19 months (open label)];MRI/MRS[At O, 3, and 7 months (crossover period), and 19 months (open label)]

Secondary Outcome Measures

Name	Time	Method
ack of adverse side effects of treatment. [At 7 months or 19 months if choose participate in the open label extension.]